HHS Expands Access to Childhood Vaccines During COVID-19 Pandemic

U.S. Department of Health and Human Services News Release 202-690-6343media@hhs.govwww.hhs.gov/newsTwitter @SpoxHHS FOR IMMEDIATE RELEASEWednesday, August 19, 2020 HHS Expands Access to Childhood Vaccines during COVID-19 Pandemic The U.S. Department of Health and Human Services (HHS) issued a third amendment to…

CLIA (Clinical Laboratory Improvement Amendments) and Why Pharmacies Care

Overview Clinical Laboratory Improvement Amendments (CLIA) was passed by Congress for non-research laboratory testing in 1988. It establishes quality standards for laboratories to ensure the accuracy, reliability, and timeliness of patient test results, regardless of where the test is performed.…

CLIA & POCT FAQ Subscriptions for Pharmacy with COVID-19 Details

Since the FDA has released new guidance, do you need to know if your state allows you to order and administer tests for COVID-19, and which tests? Bula now offers 6-month subscriptions to five Clinical Laboratory Improvement Amendments (CLIA) and…

Coronavirus (COVID-19) Legislative Update: A Letter From Our Vice President

Good afternoon, We have recently seen Executive Orders or new subregulations waiving or suspending an existing regulation or statute, if temporarily, during the crisis.  These updates are in the Current law Database, but to help you identify these quickly, enclosed is a…

A Letter from Bula: Coronavirus (COVID-19) Update

Good afternoon, Thank you all for the fantastic feedback we’ve received following our updates. The Bula team worked over the weekend to publish the following sub-regulations, and you’ll find them listed below and in the Current Law Database. Many states…

Taking a Stand on CBD Oil: The Pros and Cons for Independent Pharmacies

Medical marijuana is a polarizing topic, especially among pharmacists. Still, even the most conservative traditional healthcare professionals are unable to deny the attraction of medical marijuana’s more controlled cousin, Cannabidiol (CBD). From the strict regulation on active ingredients (only .03% THC is permissible under the 2014 Farm Bill section 7606), to the staggering profit margins (40-50%, on average), CBD seems to be the miracle product that could financially offset the diminishing returns on more traditional pharmaceuticals.